MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Clinical Trials

5.0k

Active:1714
Completed:2498

Trial Phases

6 Phases

Early Phase 1:2
Phase 1:2258
Phase 2:662
+3 more phases

Drug Approvals

69

SFDA:52
NMPA:17

Drug Approvals

Elranatamab Injection

Product Name
易瑞欧
Approval Number
国药准字SJ20250011
Approval Date
Mar 4, 2025
NMPA

Elranatamab Injection

Product Name
易瑞欧
Approval Number
国药准字SJ20250010
Approval Date
Mar 4, 2025
NMPA

Rimegepant Sulfate Orally Disintegrating Tablets

Product Name
乐泰可
Approval Number
国药准字HJ20240004
Approval Date
Jan 23, 2024
NMPA

Ritlecitinib Tosylate Capsules

Product Name
乐复诺
Approval Number
国药准字HJ20230118
Approval Date
Oct 18, 2023
NMPA

Azithromycin for injection

Product Name
希舒美
Approval Number
国药准字HJ20130831
Approval Date
Sep 22, 2023
NMPA

Azithromycin for Injection

Product Name
希舒美
Approval Number
国药准字HJ20130830
Approval Date
Sep 22, 2023
NMPA

Azithromycin for Injection

Product Name
希舒美
Approval Number
国药准字HJ20140685
Approval Date
Sep 22, 2023
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220031
Approval Date
Apr 8, 2022
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220029
Approval Date
Apr 8, 2022
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220030
Approval Date
Apr 8, 2022
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (3919 trials with phase data)• Click on a phase to view related trials

Phase 1
2258 (57.6%)
Phase 3
674 (17.2%)
Phase 2
662 (16.9%)
Phase 4
233 (5.9%)
Not Applicable
86 (2.2%)
phase_1_2
3 (0.1%)
Early Phase 1
2 (0.1%)
phase_2_3
1 (0.0%)

A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

Not Applicable
Recruiting
Conditions
Healthy Adults
Interventions
First Posted Date
2025-09-30
Last Posted Date
2025-09-30
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT07198035
Locations
🇧🇪

Pfizer Clinical Research Unit - Brussels, Brussels, Other, Belgium

A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings

Completed
Conditions
Severe Alopecia Areata
Interventions
First Posted Date
2025-09-30
Last Posted Date
2025-09-30
Lead Sponsor
Pfizer
Target Recruit Count
123
Registration Number
NCT07200128
Locations
🇺🇸

Pfizer, New York, New York, United States

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Not Applicable
Not yet recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: Portia (EE and LN) or equivalent oral tablet
First Posted Date
2025-09-24
Last Posted Date
2025-09-24
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT07190430

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Not yet recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: Non-Interventional Study
First Posted Date
2025-09-16
Last Posted Date
2025-09-16
Lead Sponsor
Pfizer
Target Recruit Count
4000
Registration Number
NCT07177209
Locations
🇬🇧

Pfizer, Walton Oaks, United Kingdom

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

Not Applicable
Recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: PF-08049820 MR1
Drug: PF-08049820 IR
Drug: PF-08049820 MR2
First Posted Date
2025-09-15
Last Posted Date
2025-09-15
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT07172321
Locations
🇺🇸

Pfizer Clinical Research Unit, New Haven, Connecticut, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 640
  • Next

News

Biopharma M&A Activity Surges in Q3 2025 with $55.7 Billion in Acquisitions

The biopharmaceutical sector experienced a significant surge in high-value acquisitions during Q3 2025, with four of the year's five largest deals occurring in the past four months.

TAHO Pharma Submits World's First Apixaban Oral Dissolving Film to FDA for Stroke Survivors with Swallowing Difficulties

TAHO Pharmaceuticals has submitted a New Drug Application to the FDA for TAH3311, the world's first apixaban oral dissolving film designed for patients with swallowing difficulties.

Indivior Halts Marketing of Controversial Overdose Drug Opvee Following New York Settlement

Indivior has discontinued marketing of Opvee, its controversial overdose-reversal medication, following a settlement with New York Attorney General Letitia James after two years of poor sales and intense scrutiny.

FDA Halts New Drug Application Acceptance as Government Shutdown Begins

The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.

Cue Biopharma Appoints Dr. Usman Azam as CEO, Pivots to Autoimmune Disease Focus with CUE-401

Cue Biopharma has appointed Dr. Usman Azam as President and CEO, effective September 29, 2025, bringing over 25 years of drug development experience including CAR-T cell therapy leadership at Novartis.

MannKind Appoints Dr. Ajay Ahuja as Chief Medical Officer to Advance Inhaled Therapeutics Pipeline

MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.

AstraZeneca Launches Direct-to-Consumer Platform with Up to 70% Drug Discounts Following Trump Administration Pressure

AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.

Pfizer Presents Breakthrough Cancer Data at ESMO 2025, Showcasing Unprecedented Survival Results

Pfizer will present data from more than 45 abstracts at ESMO 2025, including unprecedented survival results from the Phase 3 EV-303 trial evaluating PADCEV plus KEYTRUDA in muscle-invasive bladder cancer patients.

Pfizer Acquires Obesity Drug Developer Metsera in Strategic Move to Enter Weight Management Market

Pfizer has announced the acquisition of Metsera, a biotechnology company focused on developing obesity treatments, marking the pharmaceutical giant's strategic entry into the rapidly growing weight management market.

FAERS Analysis Reveals Lower Infection Risk with Ide-cel Compared to Other BCMA-Targeted Therapies in Multiple Myeloma

A retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from 2021-2024 found that idecabtagene vicleucel (ide-cel) was associated with significantly lower infection rates compared to other BCMA-directed therapies in multiple myeloma patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.